logo
  

Macerich Revises 2021 Earnings Outlook- Quick Facts

Real estate investment trust Macerich Company (MAC) has revised its full-year outlook for earnings and FFO per share after reflecting the common stock sold to date, and the pending sale of 95% interest in Paradise Valley Mall.

Through March 25, 2021, the Company has sold 36 million common shares under its "at the market" equity program at $13.54 per share.

Macerich currently sees loss per share to be in the range of $0.73 - $0.53 in the full-year.

On average 9 analysts polled by Thomson Reuters expect the company to report loss of $0.69 per share for the period.

Full-year FFO per share is expected in the range of $1.77- $1.97.

Also, the comany said it has obtained commitments from its joint lead lenders, Deutsche Bank, JPMorgan, and Goldman Sachs for a new revolving line of credit and credit facility of between $600 million and $800 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
Follow RTT